Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00022-06PMID 16723585PMCID PMC1479139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The activity and inhibition of the food vacuole plasmepsin from the rodent malaria parasite Plasmodium chabaudi.

  2006cited by this paper
• The Role of Plasmodium falciparum Food Vacuole Plasmepsins*

  2005cited by this paper
• Antimalarial effects of HIV proteinase inhibitors: common compounds but structurally distinct enzymes.

  2005cited by this paper
• Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors

  2005cited by this paper
• Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.

  2005cited by this paper
• Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum.

  2005cited by this paper
• Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.

  2004influential reference
• Cysteine proteases of malaria parasites.

  2004cited by this paper
• Antiretrovirals as antimalarial agents.

  2004cited by this paper
• Aspartic Peptidase Inhibitors: Implications in Drug Development

  2003cited by this paper
• Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite.

  2003cited by this paper
• Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine

  2002cited by this paper
• Comparison of Efficacies of Cysteine Protease Inhibitors against Five Strains of Plasmodium falciparum

  2001cited by this paper
• Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors

  1998cited by this paper
• Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor).

  1992cited by this paper

• Repurposing amide-based drugs unveils inhibition mechanisms of plasmodium falciparum Plasmepsin V enzymatic activity for antimalarial therapy.

  2026cites this paper
• Identifying thiourea-based hybrids of quinazoline and oxospirochromane as inhibitors of Plasmodium cysteine proteases arresting the parasitic growth at the early trophozoite stage.

  2025cites this paper
• From Conventional Treatment to Targeted Antimalarial Therapy: Building Up on Innovations

  2021cites this paper
• Estudio del efecto de péptidos sintéticos derivados de proteínas de Plasmodium falciparum sobre el flujo de calcio en glóbulos rojos

  2019cites this paper
• Preliminary Results Indicate the Anti-Proliferative Effect of HIV-1 Protease Inhibitors on Trypanosoma brucei Cells can be Due to the Non-Specific Targeting of Metallo-and Cysteine-Proteases

  2019cites this paper
• Chemical Digestion, Absorption, and Transport

  2018cites this paper
• Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of the malaria parasite.

  2018cites this paper
• Buy one, get one free? Benefits of certain antiretrovirals against malaria.

  2017cites this paper
• The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi.

  2017cites this paper
• Comprehensive review on various strategies for antimalarial drug discovery.

  2017cites this paper
• Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060

  2016cites this paper
• Defining the targets of antiparasitic compounds.

  2016cites this paper
• Modulation of Human and Malarial Glucose Transporter Activity by Lipids and Small Molecules

  2016cites this paper
• Investigation of Novel Antimalarial Agents and Novel Target Identification Approaches

  2015influential citation
• The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir

  2015cites this paper
• "Recycling" classical drugs for malaria.

  2014cites this paper
• Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.

  2014cites this paper
• HIV treatments have malaria gametocyte killing and transmission blocking activity.

  2013cites this paper
• Transmitted drug resistance in French HIV-2-infected patients

  2013cites this paper
• New approaches in antimalarial drug discovery and development: a review.

  2012cites this paper
• HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.

  2012cites this paper
• Novel drug targets in malaria parasite with potential to yield antimalarial drugs with long useful therapeutic lives.

  2012cites this paper
• Linear and cyclic dipeptides with antimalarial activity.

  2012cites this paper
• Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds.

  2012cites this paper
• Virtual High Screening Combining Docking and 3D QSAR Protocols in Identifying Plasmepsin II Enzyme Inhibitors of Plasmodium Falcipurum

  2012cites this paper
• In Vitro Activity of Antiretroviral Drugs against Plasmodium falciparum

  2011cites this paper
• HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites

  2011cites this paper
• The Plasmepsin Family as Antimalarial Drug Targets

  2011cites this paper
• A novel antimalarial lead compound: in vitro properties and mode of action studies

  2011cites this paper
• Expanding the Antimalarial Drug Arsenal—Now, But How?

  2011cites this paper
• Proteases of Plasmodium falciparum as potential drug targets and inhibitors thereof.

  2010cites this paper
• Challenges to the treatment of malaria

  2010cites this paper
• HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

  2009cites this paper
• Antimalarial Activity of Ultra-Short Peptides

  2009cites this paper
• Targeting the plasmepsin 4 orthologs of Plasmodium sp. with "double drug" inhibitors.

  2008cites this paper
• Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum

  2008cites this paper
• HIV and malaria co-infection: interactions and consequences of chemotherapy.

  2008cites this paper
• Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function

  2007cites this paper
• Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro

  2006cites this paper